I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Ujjani C
84
results:
Search for persons
X
Format
Online (84)
Mediatypes
Articles (Online) (47)
OpenAccess-fulltext (37)
Sorted by: Relevance
Sorted by: Year
?
1
Ibrutinib and Venetoclax in Relapsed and Refractory Follicu..:
Ujjani, C.
;
Wang, H.
;
Broome, C.
...
Hematological Oncology. 41 (2023) S2 - p. 381-382 , 2023
Link:
https://doi.org/10.1002/..
?
2
Response‐adapted mosunetuzumab for untreated follicular and..:
Lynch, R. C.
;
Poh, C.
;
Shadman, M.
...
Hematological Oncology. 41 (2023) S2 - p. 577-578 , 2023
Link:
https://doi.org/10.1002/..
?
3
S207: EFFICACY AND SAFETY OF A THIRD GENERATION CD20 CART (..:
Shadman, M.
;
Yeung, C.
;
Redman, M.
...
HemaSphere. 6 (2022) - p. 108-109 , 2022
Link:
https://doi.org/10.1097/..
?
4
P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL..:
Mato, A. R.
;
Manzoor, B. S.
;
Coombs, C. C.
...
HemaSphere. 6 (2022) - p. 569-570 , 2022
Link:
https://doi.org/10.1097/..
?
5
S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVE..:
Mato, A. R.
;
Pagel, J. M.
;
Coombs, C. C.
...
HemaSphere. 6 (2022) - p. 48-49 , 2022
Link:
https://doi.org/10.1097/..
?
6
Pilot Prognostic Model for Survival in r/r DLBCL Patients R..:
Eastman, B.
;
Hippe, D.S.
;
Smith, S.C.
...
International Journal of Radiation Oncology*Biology*Physics. 111 (2021) 3 - p. e299-e300 , 2021
Link:
https://doi.org/10.1016/..
?
7
A WINDOW STUDY OF IXAZOMIB IN UNTREATED B‐NHL:
Graf, S.A.
;
Lynch, R.C.
;
Ujjani, C.
...
Hematological Oncology. 37 (2019) S2 - p. 570-571 , 2019
Link:
https://doi.org/10.1002/..
?
8
PHASE IB/II STUDY OF IBRUTINIB AND VENETOCLAX IN RELAPSED A..:
Ujjani, C.
;
Wang, H.
;
Leslie, L.
..
Hematological Oncology. 37 (2019) S2 - p. 569-570 , 2019
Link:
https://doi.org/10.1002/..
?
9
Major clinical response to nivolumab in relapsed/refractory..:
Yared, J A
;
Hardy, N
;
Singh, Z
...
Bone Marrow Transplantation. 51 (2016) 6 - p. 850-852 , 2016
Link:
https://doi.org/10.1038/..
?
10
PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE ..:
Cheah, C. Y.
;
Shah, N. N.
;
Jurczak, W.
...
Hematological Oncology. 41 (2023) S2 - p. 153-156 , 2023
Link:
https://doi.org/10.1002/..
?
11
HIGH EFFICACY AND FAVORABLE SAFETY OF 3RD GENERATION CD20 C..:
Shadman, M.
;
Yeung, C.
;
Redman, M.
...
Hematological Oncology. 41 (2023) S2 - p. 87-88 , 2023
Link:
https://doi.org/10.1002/..
?
12
A PILOT TRIAL OF ADRIAMYCIN, PEMBROLIZUMAB, VINBLASTINE AND..:
Lynch, R.C.
;
Smith, S.D.
;
Shadman, M.
...
Hematological Oncology. 37 (2019) S2 - p. 572-573 , 2019
Link:
https://doi.org/10.1002/..
?
13
Treatment Discontinuation Patterns for Patients With Chroni..:
Shadman, M
;
Manzoor, BS
;
Sail, K
...
https://discovery.ucl.ac.uk/id/eprint/10171712/1/Treatment%20Discontinuation%20CLL.pdf. , 2023
Link:
https://discovery.ucl.ac..
?
14
P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REV..:
Eyre, T. A
;
Wang, M. L
;
Shah, N. N
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430028/. , 2022
Link:
http://www.ncbi.nlm.nih...
?
15
Targeted Therapy for Relapsed/Refractory Follicular Lymphom..:
Raychaudhuri R
;
Ujjani C
https://www.dovepress.com/targeted-therapy-for-relapsedrefractory-follicular-lymphoma-focus-on-c-peer-reviewed-fulltext-article-OTT. , 2022
Link:
https://doaj.org/article..
1-15